For the year ending 2025-12-31, CCCC made $35,947K in revenue. -$104,997K in net income. Net profit margin of -292.09%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue from collaboration agreements | 35,947 | 35,584 | ||
| Research and development | 104,240 | 110,637 | ||
| General and administrative | 36,196 | 42,124 | ||
| Impairment loss on right-of-use asset | 10,733 | - | ||
| Restructuring | 0 | 2,437 | ||
| Total operating expenses | 151,169 | 155,198 | ||
| Loss from operations | -115,222 | -119,614 | ||
| Interest and other income, net | 10,349 | 14,429 | ||
| Total other income, net | 10,349 | 14,429 | ||
| Loss before income taxes | -104,873 | -105,185 | ||
| Income tax expense | 121 | 131 | ||
| Net loss | -104,994 | -105,316 | ||
| Unrealized (loss) gain on marketable securities | -3 | 180 | ||
| Comprehensive loss | -104,997 | -105,136 | ||
| Basic EPS | -1.27 | -1.52 | ||
| Diluted EPS | -1.27 | -1.52 | ||
| Basic Average Shares | 82,894,459 | 69,372,993 | ||
| Diluted Average Shares | 82,894,459 | 69,372,993 | ||
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)